New GLP-1 drugs compared

US product status is separate from trial results. Wegovy injection and tablets are separate entries. Sources checked 30 August 2026; the REDEFINE 4 report directly compares CagriSema with tirzepatide. Percentages from different trials are not head-to-head results or personal forecasts.

• FDA: Foundayo approval, 1 April 2026
• FDA: Wegovy injection and tablets, January 2026 label
• Lilly: US Zepbound prescribing information
• FDA: unapproved GLP-1 products
• Lilly: TRIUMPH-1 sponsor report, 21 May 2026
• Novo Nordisk: REDEFINE 4 sponsor report, 23 February 2026